Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240008 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL1772581 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL485571 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL28766822 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL1809800 | 0.98 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL5196791 | 0.95 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1115400 | 0.95 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL1809798 | 0.95 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL644319 | 0.95 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11MAPTCYP3A4 | |
| SCHEMBL1433032 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3967714-B1 | VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-07 | — | — | EP | claimed |
| CN-118164897-A | Spirotemporal compound and preparation method and application thereof | 南开大学 | 2024-06-11 | — | — | CN | claimed |
| CN-117886737-A | Spiroteine framework compound and preparation method and application thereof | 安徽农业大学 | 2024-04-16 | — | — | CN | claimed |
| CN-115417790-A | Novel azo foaming agent and synthesis method thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| US-20200317615-A1 | PALLADIUM (II)-CATALYZED gammaC(SP3)-H ALKYNYLATION OF AMINE2 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | US | claimed |
| US-10787418-B1 | Palladium (II)-catalyzed γC(SP3)-H alkynylation of amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-29 | — | — | US | claimed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3967714-B1 | VINYL ALCOHOL-AMINO ACID ESTER COPOLYMER, THEIR PREPARATION AND USES | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12435165-B2 | Vinyl alcohol-amino acid ester copolymer | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| CN-119080976-A | Vinyl alcohol-amino acid ester copolymer | 积水化学工业株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-118164897-B | Spirotemporal compound and preparation method and application thereof | 南开大学 | 2024-11-15 | — | — | CN | disclosed |
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-113795520-B | Vinyl alcohol-amino acid ester copolymer | 积水化学工业株式会社 | 2024-08-30 | — | — | CN | disclosed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5512681-A | HORMONE INHIBITORS FOR TREATMENT OF HYPERTENSION OR CONGESTIVE HEART FAILURE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0601039-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLINONE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0249434-B1 | Peptide derivatives and processes for their preparation | VYZK USTAV FARM BIOCHEM SP (CZ) | 1994-05-04 | — | — | EP | disclosed |
| US-4898930-A | Peptide derivatives and processes for their preparation | SPOFA, SPOJENE PODNIKY PRO (CS) | 1990-02-06 | — | — | US | disclosed |
| EP-0249434-A2 | Peptide derivatives and processes for their preparation | Vyzkumny ustav pro farmacii a biochemii (CZ) | 1987-12-16 | — | — | EP | disclosed |
| US-4610817-A | N-acyl derivatives of peptides, their preparation and their use in the treatment of disorders, and agents for this purpose | BASF AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | NPSR1 670/4885CYP4F2 1433/4885CYP4A11 552/4885 |
| US-20200317615-A1 | PALLADIUM (II)-CATALYZED gammaC(SP3)-H ALKYNYLATION OF AMINE2 | POLE3, BUB3, POLR2H | NPSR1 743/4885CYP4F2 3214/4885CYP4A11 4058/4885 |
| US-10787418-B1 | Palladium (II)-catalyzed γC(SP3)-H alkynylation of amines | POLE3, BUB3, POLR2H | NPSR1 433/4885CYP4F2 3757/4885CYP4A11 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.